Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00136344
Other study ID # MREC Ref. no. 02/5/46
Secondary ID
Status Completed
Phase N/A
First received August 26, 2005
Last updated February 11, 2016
Start date September 2003
Est. completion date May 2006

Study information

Verified date June 2007
Source City University, London
Contact n/a
Is FDA regulated No
Health authority United Kingdom: National Health Service
Study type Interventional

Clinical Trial Summary

Cataract is the most important cause of visual impairment and decreased mobility in the elderly. While surgery is usually successful, it is also responsible for permanent loss of vision in up to 0.1% of patients due to severe post-operative infection (endophthalmitis). Because of this risk, surgery is typically performed on one eye at a time leaving the patient with a monocular cataract causing considerable visual impairment with reduction in mobility and quality of life. A second operation is required which often takes place up to one year later.

It is not known at present whether the post-operative complication of endophthalmitis can be prevented by perioperative use of antibiotics. This randomised study (masked and placebo-controlled for topical levofloxacin and unmasked for intracameral injection of cefuroxime) sets out to test in 4 groups, each of 8,750 cataract surgery patients, if either topical antibiotic (levofloxacin) perioperatively or an intraocular (intracameral) injection of antibiotic (cefuroxime) at the end of phacoemulsification cataract surgery or the combination provides effective prophylaxis of post-operative infection (endophthalmitis) compared to controls in whom perioperative antibiotics are not used. The result will provide a scientific basis for prophylaxis of infection (endophthalmitis) following cataract surgery in Europe as well as an accurate figure for the incidence of endophthalmitis following phacoemulsification cataract surgery in Europe for the first time.


Description:

Cataract extraction with intra-ocular lens implantation is the most commonly performed surgical procedure in the elderly population in Europe. The frequency varies in different European Union (EU) countries involving 2 to 7 per 1000 population per annum. A population with an ever-increasing proportion of the elderly is advancing this figure with numbers requiring surgery expected to increase by 70% by 2006. While technical advances (phacoemulsification) have enhanced the efficacy of the procedure, the possibility of serious post-operative infection with loss of vision remains the most important unsolved problem.

In the absence of scientific evidence, the European Society of Cataract and Refractive Surgeons (ESCRS) wishes to determine whether one currently developed method of delivering antibiotics intraocularly in Sweden is of benefit compared to surgery without the use of perioperative antibiotics, as currently practised in many European centres, or to the use of frequent application of topical antibiotic drops perioperatively. The ESCRS also wishes to assess possible risk factors for later endophthalmitis.

This study requires four groups of 8,750 patients - 35,000 in all - to demonstrate reductions of currently reported rates of endophthalmitis (approximately 0.3%) in patients where no intraocular antibiotics are used, or where they are used by the subconjunctival route. Other studies using intraocular vancomycin have reported results as low as 0.05%, but these studies were not standardised or controlled and the results were anecdotal. In addition, vancomycin should not be used for routine prophylaxis and should only be used as the antibiotic of 'last resort'.

This multi-centre randomised study involves 24 operating units in 8 EU countries (Austria, Belgium, England, Germany, Italy, Poland, Portugal and Spain) and Turkey. Results in 8,750 patients receiving an intracameral injection of antibiotic (cefuroxime) at the end of surgery will be compared to 8,750 patients receiving topical antibiotic (levofloxacin) prophylaxis before and at the end of surgery, 8,750 patients receiving the combination and 8,750 patients receiving neither regime; in addition, all patients will receive povidone iodine antiseptic prophylaxis prior to surgery and post-operative levofloxacin from days 1 to 6 to prevent wound infection.

This group size will be sufficiently large to ensure at least 80% statistical power to detect a reduction of incidence from 0.25% to 0.08% using 5% significance level tests.

Surgical data from all patients will be collected directly into computers based within each operating theatre and transmitted to a central server in Glasgow (University of Strathclyde). Follow-up data for the presence or absence of endophthalmitis will be collected from all patients at post-operative visits and similarly recorded on computers for transmission to the central server. Sophisticated techniques will be used to check all data as it is uploaded.


Recruitment information / eligibility

Status Completed
Enrollment 35000
Est. completion date May 2006
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- All patients, including diabetics, undergoing routine cataract surgery in each unit taking part in the study

Exclusion Criteria:

- Patients who do not wish to take part in the trial

- Patients allergic to penicillins and cephalosporins.

- Long-term nursing home patients

- Patients with only one eye

- Pregnancy.

- Children less than 18 years old.

- All severely 'at-risk' groups for infection including:

- Severe atopic keratoconjunctivitis;

- Severe active blepharitis;

- Ocular cicatricial pemphigoid.

- Patients with complicated cataracts such as traumatic or subluxated

- Patients having combined operations with cataract surgery such as trabeculectomy or a corneal graft.

- Patients known to be allergic to povidone iodine (very rare) or any other known hypersensitivity to any components of the study medications.

- Patients who are incapacitated mentally and incapable of giving consent.

- Patients with severe thyroid disease

- Open infection anywhere, infection of lacrimal drainage channels or infection around the eye

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Cefuroxime

Levofloxacin


Locations

Country Name City State
Austria University Eye Clinic, Paracelsus Private Medical University Salzburg
Belgium University Hospital Antwerp, UZA Ophthalmology Antwerp
Belgium University of Gent, Universitaire Zeikenhuis Gent
Belgium Jan Yperman Ziekenhuis Ieper
Belgium Centre Hospitalier Universitaire Liege
Belgium Oogheelkunde Melveren
Germany Augenklinik Ahaus Ahaus
Italy Azienda Ospedaliera di Desenzano del Garda Desenzano
Italy Ospedale Borgo Trento Verona
Poland Kierownik Katedry i Kliniki Warsaw
Portugal University Hospital Coimbra
Spain Instituto Oftalmologico VISSUM Alicante
Spain La Candelaria University Hospital La Candelaria, Tenerife
Spain Hospital Universitario de Canarias La Laguna, Tenerife
Spain Hospital Oftalmologico Internacional Madrid
Turkey Dokuz Eylul University Izmir
United Kingdom Axminster Hospital Axminster
United Kingdom West of England Eye Unit, Royal Devon & Exeter Hospital (Wonford) Exeter
United Kingdom Ipswich Hospital Ipswich
United Kingdom Moorfields Eye Outreach Unit, Northwick Park Hospital London
United Kingdom Moorfields Eye Outreach Unit, St. George's Hospital London
United Kingdom St. Thomas' Hospital London
United Kingdom Oxford Eye Hospital Oxford
United Kingdom Sunderland Eye Infirmary Sunderland

Sponsors (3)

Lead Sponsor Collaborator
City University, London Santen Gmbh, The European Society of Cataract and Refractive Surgeons(ESCRS)

Countries where clinical trial is conducted

Austria,  Belgium,  Germany,  Italy,  Poland,  Portugal,  Spain,  Turkey,  United Kingdom, 

References & Publications (3)

Barry P, Seal DV, Gettinby G, Lees F, Peterson M, Revie CW; ESCRS Endophthalmitis Study Group. ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery: Preliminary report of principal results from a European multicenter study. J — View Citation

Endophthalmitis Study Group, European Society of Cataract & Refractive Surgeons. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 2 — View Citation

Seal DV, Barry P, Gettinby G, Lees F, Peterson M, Revie CW, Wilhelmus KR; ESCRS Endophthalmitis Study Group. ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery: Case for a European multicenter study. J Cataract Refract Surg. 2006 Mar;32(3):396-406. Erratum in: J Cataract Refract Surg. 2006 May;32(5):709. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Prevention of post-operative endophthalmitis following phacoemulsification cataract surgery in Europe due to use of perioperative antibiotics
Primary Incidence of endophthalmitis in Europe following phacoemulsification cataract surgery
Secondary Effect of risk factors on the presentation of endophthalmitis in Europe following phacoemulsification cataract surgery
See also
  Status Clinical Trial Phase
Recruiting NCT04214821 - The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5% Phase 1/Phase 2
Completed NCT00461656 - Povidone-iodine Antisepsis for Strabismus Surgery Phase 4
Completed NCT04568213 - Hypochlorous Acid Disinfection Prior to Cataract Surgery Phase 3
Terminated NCT01496794 - Endophthalmitis Cultures N/A
Completed NCT00406913 - Prophylaxis Prior to Cataract Surgery Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery N/A
Recruiting NCT05079854 - Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis Phase 4
Recruiting NCT05432336 - Complex Ocular Infection, Optimization of Microbiological Diagnosis
Recruiting NCT02810587 - Endophthalmitis After Intravitreous Anti-VEGF Injections in Patients Receiving vs. Not Receiving Topical Antibiotics N/A
Completed NCT00398658 - Prophylaxis of Acute Post-Traumatic Bacterial Endophthalmitis Phase 4
Recruiting NCT04035369 - Endophthalmitis Post Intravitreal Injections N/A
Not yet recruiting NCT03420820 - Concentrating on Antisepsis: 5% vs. 10% Povidone-Iodine Prior to Intravitreal Injection N/A
Recruiting NCT06268561 - Ozurdex Endophtamitis Cohort, Prognostic Assessment at 12 Months
Withdrawn NCT00335231 - Preoperative Topical Gatifloxacin on Anterior Chamber Cultures After Cataract Surgery N/A
Not yet recruiting NCT03244072 - Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery Phase 2/Phase 3
Completed NCT01323868 - Endogenous Endophthalmitis in the Inpatient Setting N/A
Completed NCT03363295 - Evaluation of Macular Changes After Intracameral Moxifloxacin for Prevention of Endophthalmitis Phase 4
Suspended NCT02590523 - Intracameral Antibiotic Safety Study Phase 3
Terminated NCT02770729 - Evaluation of Efficacy and Safety of Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis. Phase 3
Not yet recruiting NCT02324166 - Cefazolin-Lidocaine Combination Solution to Reduce Antibiotic Pain Phase 4
Completed NCT02595359 - Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis Phase 2